David J. Cohen, MD, MSc Matthew Herper These types of studies should come with a boxed warning: Caveat Lector, Caveat Emptor! Or better still, not published!

Let's go! #ESCCongress

BedMed #ESCCongress Hotline…

BedMed- Effect of antihypertensive timing on mortality and morbidity #ESCHotline #ESCCongress #LBCT #CVPrev Does Administration time of anti HTN matter? 🫀1677pt, median age of 67 y, 56% 💃🏻, meds at 🌞am 🆚 pm 🌓 📍ultimately no difference seen 📍 no subgroup diff

BedmedFrail #LBCT #ESCCongress #LBCT #ESCHotline 📍 776 patients randomized, high pragmatic enrollment 📍⤴️💃🏻-70%+ 📍no difference in timing of meds except for all-cause unplanned hospitalisation/ED visits, which favoured bedtime use Take BP meds when you remember! #CVprev

Meta-analysis of all trials related to timing of treatment agree that time of meds just doesn’t matter! #ESCCongress #ESCHotline #cvPrev #HTN 📍 no difference in all-cause mortality for evening and morning dosing (HR 0.77; 95% CI 0.51–1.16)

Meta-analysis of trials investigating bedtime vs morning administration of anti-hypertensive therapy (Chronotherapy). Despite hterogeneity, redults were neutral. Time to abandon this concept once for all! #ESCCongress 2024 #CardioTwitter #CardioEd Erika Campana “OTO PA-TA-MAR” ❤️🖤 Kevin Fernando

In a meta-analysis of five trials designed to test evening vs. morning dosing, no difference was found in the incidence of major cardiovascular events, deaths or safety events. bit.ly/4g1KoqZ #ESCCongress

#ESCCongress 2024 HOT LINES 2 delivers 🔥 #science with much awaited BedMed & BedMed-Frail RCTs - Effect of antihypertensive timing on mortality & morbidity Congrats to 🇨🇦 investigators led by Dr Garrison for impt contributn AND incl equal proportn of females👏 🎯

#ESC2024 Dusk or Dawn - all the same. Take your BP meds, no matter when. BedMed & BedMed-Frail RCT by Dr. Garrison + Meta-analysis of trials of antihypertensive med bedtime dosing by Ricky Turgeon PharmD @dgfn ÖGN - Österreichische Gesellschaft für Nephrologie SFNDT D.Guerrot Florian Custodis marcus_saemann Swapnil Hiremath @[email protected]

This hot take is the correct take. Clinicians, don't get stuck in your status quo by your loss aversion!

Looks like the closest we'll get to data of apixaban vs placebo in AF. Congratulations apixaban on crossing this milestone!

So powerful to hear voices of those with lived experience at our #ESCCongress sessions. Optimal design of #clinicaltrials, healthcare #services, and #implementation strategies must include the voices of our patients.. sounds obvious, but often overlooked. #PatientCentredCare

Two new Ottawa-style patient decision aids for patients considering mavacamten for obstructive HCM, created by UBC Pharm Sci student Ruishen Yu: decisionaid.ohri.ca/AZsumm.php?ID=… (not considering or ineligible for septal reduction therapy [SRT]) decisionaid.ohri.ca/AZsumm.php?ID=… (considering SRT)

#UBC Pharm Sci's Ricky Turgeon PharmD explained that patients should take their once-daily blood pressure-lowering tablets at whatever time best suits them in recent European Society of Cardiology press release - escardio.org/The-ESC/Press-… #BloodPressure #CardiovascularEvents

sciencedirect.com/science/articl… Stage 1 of the INSPECT-SR project, now published in Journal of Clinical Epidemiology

In July 2023, the European Medicines Agency announced an investigation into reports that GLP-1 receptor agonist weight loss drugs, like #ozempic, might increase the risk of suicide and self-harm. Is this link plausible? New data is just out. Brief 🧵...

I dream of being as timely and transparent in my work communication as our local farm

Updated summary for MRAs in heart failure with ejection fraction >40% including TOPCAT, FINEARTS-HF, & the Lancet IPD meta-analysis: nerdcat.org/studysummaries… IMO, clear class effect of MRAs in these patients. Remains important to walk the efficacy/safety trade-off tightrope

To sum up: the frequent omission of EPIC-SR highlights the significant bias in reporting of clinical trial results, particularly those with negative outcomes. This selective reporting continues to skew the perceived effectiveness of treatments like Paxlovid. End 🧵10/10